News Breaks |
|
|
| June 13, 2012 |
| 10:16 EDT |  | REGN, RHHBY | Regeneron drops 6% after Ophthotech reports positive data
Privately-held Ophthotech this morning announced results from its first clinical trial to show statistically significant superior efficacy over Roche's (RHHBY) Lucentis monotherapy for the treatment of neovascular age-related macular degeneration, or wet AMD. In a Phase 2b clinical trial of 449 patients with wet AMD, Ophthotech’s Fovista anti-PDGF therapy, administered in combination with Lucentis anti-VEGF therapy, met the pre-specified primary efficacy endpoint of mean vision gain. Patients receiving the combination of Fovista and Lucentis gained a mean of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, compared to 6.5 letters for patients receiving Lucentis monotherapy, representing a 62% additional benefit. Shares of Regeneron (REGN) are trading down 6.4%, or $8.13, to $117.91 following Ophthotech's trial results. Regeneron's Eylea drug also treats wet AMD, making Ophthotech's Fovista a potential competitor. |
|
|
News For REGN;RHHBY From The Last 14 Days Check below for free stories on REGN;RHHBY the last two weeks. |
|
|
| May 23, 2013 |
| 15:19 EDT |  | RHHBY | FDA announces approval of Roche diabetes test
 Subscribe for More Information |
|
| May 22, 2013 |
| 12:25 EDT |  | REGN | Stocks with call strike movement; GME REGN
Subscribe for More Information |
|
| 10:33 EDT | | RHHBY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:00 EDT |  | RHHBY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:02 EDT | | RHHBY | Roche upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT |  | RHHBY | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| May 20, 2013 |
| 19:01 EDT | | REGN | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 17:26 EDT | | REGN, RHHBY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT | | REGN, RHHBY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 07:28 EDT |  | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
| |
| May 17, 2013 |
| 10:07 EDT |  | REGN | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:16 EDT | | REGN | Regeneron initiated with a Neutral at UBS
Subscribe for More Information |
|
| 06:33 EDT | | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 15:59 EDT | | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information |
|
| 12:13 EDT | | RHHBY | Roche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT | | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
|
| 05:39 EDT | | REGN | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 14, 2013 |
| 16:55 EDT | | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
|
| 07:34 EDT |  | REGN | Regeneron outlook positive, says RBC Capital
Subscribe for More Information |
|
| May 13, 2013 |
| 08:55 EDT | | RHHBY | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
| |
|
|
|
|
